Novo Falls by Most on Record After New Weight Drug Disappoints.

Novo Nordisk A/S's shares experienced a significant drop after patients using its new obesity shot, CagriSema, did not lose as much weight as expected in a study. The shot resulted in an average weight loss of 22.7% over 68 weeks for those who adhered to the treatment, falling short of the 25% predicted by Novo. This development raises concerns about Novo's competitiveness in the expanding weight-loss drug market, which is expected to reach nearly $130 billion by 2030. Eli Lilly & Co.'s shares, on the other hand, saw a 7.6% increase following the news. [Extracted from the article]